Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVCT.LSE
- Price
- 77.10
- Stock movement up
- +0.10 (0.13%)
- Company name
- Avacta Group PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 334.35M
- Ent value
- 350.80M
- Price/Sales
- 14.78
- Price/Book
- 2321.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 79.30%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
AVCT.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 14.78 |
| Price to Book | 2321.91 |
| EV to Sales | 15.51 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 433.66M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.64M |
| Net receivables | 3.01M |
| Total current assets | 21.99M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.10M |
| Total assets | 29.24M |
| Accounts payable | 6.60M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 27.90M |
| Total liabilities | 29.09M |
| Shareholder's equity | 144.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 76.40 |
| Daily high | 79.00 |
| Daily low | 75.00 |
| Daily Volume | 1.27M |
| All-time high | 82.50 |
| 1y analyst estimate | 81.25 |
| Beta | -0.19 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AVCT.LSE | S&P500 | |
| Current price drop from All-time high | -6.55% | -1.08% |
| Highest price drop | -57.43% | -19.00% |
| Date of highest drop | 23 May 2025 | 8 Apr 2025 |
| Avg drop from high | -27.05% | -2.64% |
| Avg time to new high | 20 days | 6 days |
| Max time to new high | 244 days | 89 days |
COMPANY DETAILS
Marketcap
334.35M
Marketcap category
Small-cap
Description
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Employees
151
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found